In mouse models of diabetes, both VDR-agonists and RAS-inhibitors blunted the development of diabetic nephropathy when given alone, but the combination (VDR-agonist + RAS-inhibitor) synergistically prevented the development of diabetic nephropathy via down-regulation of the renal-vascular tissue-RAS [19-21]. The gene discussed is VDR; the disease is diabetic kidney disease.